An evident trend was observed in nasal sIgA levels which were high at baseline and by day 30 gradually returned to normal, i.e. the levels seen in healthy subjects with no history of exposure to SARS-CoV-2 (unvaccinated, not infected).
← all excerpts
Secretory IgA and course of COVID-19 in patients receiving a bacteria-based immunostimulant agent in addition to background therapy.
1
—
—